Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 5

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 5
---
 on its active preclinical projects
in its SEC filings and/or press releases, as appropriate.

We may not be successful in our efforts
to identify or discover additional drug candidates. Due to our limited resources and access to capital, we must continue to prioritize
development of certain drug candidates; such decisions may prove to be wrong and may adversely affect our business.

Although we intend to explore
other therapeutic opportunities in addition to the drug candidates that we are currently developing, we may fail to identify other drug
candidates for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential drug candidates
or those we identify may be shown to have harmful side effects or other undesirable characteristics that make them unmarketable or unlikely
to receive regulatory approval.

Research programs to pursue
the development of our drug candidates for additional indications and to identify new drug candidates and disease targets require substantial
technical, financial and human resources whether or not we ultimately are successful. Our research programs may initially show promise
in identifying potential indications and/or drug candidates, yet fail to yield results for clinical development for a number of reasons,
including but not limited to:

  the research methodology used may not be successful in identifying potential indications and/or drug candidates;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  potential drug candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal rese...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Because we have limited financial
and managerial resources, we have chosen to focus at present on our three Lead Projects, which may ultimately prove to be unsuccessful.
As a result of this focus, we may forego or delay pursuit of opportunities with other drug candidates, or for other indications that later
prove to have greater commercial potential or a greater likelihood of success. Even if we determine to pursue alternative therapeutic
or diagnostic drug candidates, these other drug candidates or other potential programs may ultimately prove to be unsuccessful. In short,
our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

According